This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huczynski, J. Articles by Gryglewski, R. J. Search for Related Content PubMed PubMed Citation Articles by Huczynski, J. Articles by Gryglewski, R. J.

Stroke, Vol 16, 810-814, Copyright © 1985 by American Heart Association

ARTICLES

Double-blind controlled trial of the therapeutic effects of prostacyclin in patients with completed ischaemic stroke

J Huczynski, E Kostka-Trabka, W Sotowska, K Bieron, L Grodzinska, A Dembinska- Kiec, E Pykosz-Mazur, E Peczak and RJ Gryglewski

In a pilot study, 26 patients with acute completed strokes (48 hours to 5 days after cerebral infarction) were randomly assigned to the prostacyclin (PGI2) or placebo groups. PGI2 sodium salt (Epoprostenol, Wellcome Research Laboratories and Upjohn Company) or its solvent (glycine buffer) were infused into the subclavian vein for six-hour periods in five courses separated by six-hour intervals. Prostacyclin was administered at a rate of 2.5-5.0 ng/kg/min. A significant alleviation of neurological deficits occurred 6 and 54 hours after the treatment in patients receiving prostacyclin. This improvement lost its statistical significance at the end of a two-week observation period. It is concluded that further modified controlled studies are required to evaluate the therapeutic usefulness of PGI2 in the treatment of patients with cerebral ischaemia.

This article has been cited by other articles:

				P. W. Duncan, H. S. Jorgensen, and D. T. Wade Outcome Measures in Acute Stroke Trials : A Systematic Review and Some Recommendations to Improve Practice Stroke, June 1, 2000; 31(6): 1429 - 1438. [Abstract] [Full Text] [PDF]